CAM
DNA icon

Cresset Asset Management’s Ginkgo Bioworks DNA Stock Holding History

Cresset Asset Management’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-4,970
Closed -$66.5K – 2200
2024
Q2 		$66.5K Sell
4,970
-4,713
-49% -$141K ﹤0.01% 1986
2024
Q1 		$449K Buy
9,683
+2,012
+26% +$104K ﹤0.01% 1386
2023
Q4 		$519K Buy
7,671
+337
+5% +$20.6K ﹤0.01% 1214
2023
Q3 		$531K Buy
7,334
+534
+8% +$42.7K ﹤0.01% 1149
2023
Q2 		$506K Buy
6,800
+5,988
+737% +$354K ﹤0.01% 1277
2023
Q1 		$43.2K Sell
812
-11
-1% -$697 ﹤0.01% 790
2022
Q4 		$55.6K Sell
823
-139
-14% -$12.8K ﹤0.01% 684
2022
Q3 		$120K Buy
962
+625
+185% +$74.5K ﹤0.01% 828
2022
Q2 		$32K Buy
+337
New +$41.1K ﹤0.01% 919

Other funds holding DNA

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Cresset Asset Management's DNA Position: Q3 2024 in Review

Cresset Asset Management sold out of Ginkgo Bioworks (DNA) in Q3 2024, closing a stake of 4,970 shares — an estimated $66.5K sold.

Cresset Asset Management first reported a position in DNA in Q2 2022 and held it in 9 quarters. The position peaked at $531K in Q3 2023. 159 funds tracked by Wall St. Rank hold DNA as of Q3 2024.

  • Cresset Asset Management reported no remaining Ginkgo Bioworks position as of Q3 2024 after selling out during the quarter.
  • Cresset Asset Management sold 4,970 Ginkgo Bioworks shares in Q3 2024, an estimated $66.5K.
  • Cresset Asset Management first reported a position in Ginkgo Bioworks in Q2 2022 and held it in 9 quarters.
  • Cresset Asset Management's Ginkgo Bioworks position peaked at $531K in Q3 2023.
  • 159 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q3 2024.

Based on Cresset Asset Management's 13F filing for Q3 2024, filed 14 Nov 2024.